End-of-life anxiety is an overwhelming experience, marked by existential fears and emotional turmoil, that affects an individual as well as their loved ones. Traditional treatments sometimes fall short in addressing the profound questions and distress tied to the final stages of life. <\/p>\n\n\n\n
This article explores how ketamine\u2014a unique therapeutic tool with rapid-acting and transformative effects\u2014can be useful in alleviating this anxiety. <\/p>\n\n\n\n
<\/p>\n\n\n\n
<\/p>\n\n\n\n
<\/p>\n\n\n\n
Facing the end of life can bring a wide range of emotions. Existential anxiety<\/strong> is common as individuals reflect on their legacy and ponder what comes after death. While such thoughts are natural, they can lead to overwhelming dread and despair for some. <\/p>\n\n\n\n According to a National Institute of Health study<\/a>, moderate-to-severe anxiety <\/strong>and depression<\/strong> may be experienced by over 40% of terminally ill patients. These symptoms can put stress on the nervous system and worsen someone\u2019s physical condition and quality of life in their final years.<\/p>\n\n\n\n Current treatments for end-of-life anxiety include cognitive-behavioral therapy (CBT)<\/strong>, which helps patients accept their circumstances and develop strategies to manage negative thoughts. Medications such as antidepressants <\/strong>and benzodiazepines<\/strong> may also provide relief from depressive and anxious thinking. However, while these approaches benefit some individuals, they often fall short of addressing profound questions about life, death, and what lies beyond.<\/p>\n\n\n\n <\/p>\n\n\n\n Since the mid-20th century, researchers have been interested in using psychedelics<\/strong> in end-of-life care. These drugs induce an altered state of consciousness<\/strong> in which people can have profound insights about life, potentially addressing existential fears. <\/p>\n\n\n\n In a 1960s study, severely ill patients were given LSD<\/strong> to reduce pain<\/a> and reported a significantly decreased fear of death after treatment. This line of research was halted after psychedelic drugs were criminalized but made a comeback in the early 2000s. <\/p>\n\n\n\n In 2016, the Johns Hopkins University<\/strong> conducted the first modern double-blind, controlled study on <\/strong>psilocybin for end-of-life distress<\/strong><\/a>. The results showed that high-dose psilocybin led to substantial reductions in measures of depression and anxiety, reduced death anxiety, and improved quality of life.<\/p>\n\n\n\n Interestingly, this study also found that positive outcomes were associated with measures of mystical experiences<\/strong>. These subjective experiences, which can be induced by spiritual practices and psychoactive drugs, are characterized by feelings of oneness <\/strong>with the universe and transcendence of time and space<\/strong>. <\/p>\n\n\n\n There are many psychological and biological factors behind why psychedelics are useful for end-of-life care. One unique property is that they influence metaphysical beliefs<\/strong>\u2014someone\u2019s views about reality and existence. One study<\/a> found that psychedelics often make individuals less materialistic<\/strong>, potentially shifting their perspective away from the idea that physical death is the absolute end. <\/p>\n\n\n\n <\/p>\n\n\n\n Ketamine has notable psychedelic features<\/strong> but isn\u2019t considered a \u201cclassical<\/strong>\u201d psychedelic like LSD or psilocybin. Classical psychedelics are known for producing vivid visual hallucinations<\/strong> and a sense of interconnectedness with the world. <\/p>\n\n\n\n In contrast, high doses of ketamine are more likely to cause physical hallucinations<\/strong>, such as the sensation of movement when the body is still, along with feelings of detachment<\/strong>. Ketamine\u2019s primary psychoactive effect is dissociation<\/strong>\u2014a sense of being separated from one\u2019s body and everyday reality.<\/p>\n\n\n\n However, there are overlaps between ketamine and classical psychedelics. People have reported having mystical experiences with ketamine and commonly experience altered perceptions about themselves and the world around them on high doses.<\/p>\n\n\n\n Moreover, ketamine and classical psychedelics have overlapping neurological mechanisms<\/strong>. These include increasing neuroplasticity<\/strong>\u2013the ability to form and reorganize nerve cell connections<\/a>, and functional connectivity<\/strong>\u2013the capacity for different brain areas to communicate. <\/p>\n\n\n\n These mechanisms allow for increased neural activity<\/strong> in key mood-regulating areas of the brain and the capacity for people to form positive thought and behavior patterns more easily. They are thought to be essential in the mental health benefits of these drugs. <\/p>\n\n\n\n <\/p>\n\n\n\n One of ketamine’s most notable features is its rapid-acting mood-enhancing<\/strong> effects. Unlike traditional antidepressants, which can take weeks to show benefits, ketamine produces noticeable improvements in mood and anxiety levels within hours<\/a>. <\/p>\n\n\n\n This swift response can be especially crucial for patients with limited time, offering an immediate sense of calm and emotional stabilization<\/strong>. Multiple studies<\/a> have demonstrated that ketamine has significant antidepressant and anti-suicide effects in cancer patients<\/strong>. <\/p>\n\n\n\n Like psychedelics, ketamine can also be used to aid psychotherapy, known as ketamine-assisted therapy<\/strong> or KAP<\/strong>. In this setting, higher doses of ketamine are used to facilitate introspection and changed perspectives. This allows individuals to confront fears around death and potentially reframe any negative beliefs. <\/p>\n\n\n\n <\/p>\n\n\n\n Spravato (esketamine) is a medication consisting of one of ketamine\u2019s two chemical components. The drug is currently approved for treatment-resistant depression (TRD) and major depressive disorder with suicidal ideation<\/a> (MDSI) only. <\/p>\n\n\n\nTreating End-of-Life Anxiety<\/strong><\/h3>\n\n\n\n
Psychedelic-Assisted Therapy for End-of-Life Anxiety<\/strong><\/h2>\n\n\n\n
Is Ketamine a Psychedelic?<\/strong><\/h2>\n\n\n\n
Ketamine to Treat End-of-Life Anxiety <\/strong><\/h2>\n\n\n\n
Spravato and End-of-Life Anxiety<\/strong><\/h2>\n\n\n\n